Finallytherock, in recent months it's been explained in far more robust terms than ever before how Bioasis can succeed. Nobody can predict with certainty that Bioasis is going to succeed, but it can be explained how Bioasis can succeed. It's clear that the many Bioasis partners have engaged with xB3 because of their beliefs in the possibilities of success with xB3.
Failure is possible, and in many ways, the company, at 13¢ a share, is no shining beacon of success. And yet we see these pharmas and biotechs lining up with Bioasis to wrangle success out of xB3.
You are quite correct about past failures, but it's no intellectual accomplishment to look at a failed past and to pronounce it a failed past. You have no bragging rights on that because it is inarguable.
You could establish some bragging rights, or at least gain a little respect from readers, if you can make some cogent arguments about why Bioasis will not succeed. Why do you think that xB3 and Bioasis will fail and why do you think that J&J/Janssen, Chiesi, Aposense, Oxyrane, Neuramedy, Daiichi Sankyo, Cresence, and others continue to put effort into determining the capabilities and value of xB3? Why are sharks like Ladenburg Thalmann and Lind involved?
Would they all do that if they expected nothing from it?
It is with respect that I ask you for your comments on this very striking difference of opinions, especially since they are all very public presences with reputations and commercial wealth to protect and enhance, and you are an anonymous presence without proven credentials.
Why will Bioasis fail?
jd